We analyzed CDX2 and SATB2 expression in two large cohorts of stages I–IV CRC patients (N = 2302) and analyzed their associations with clinicopathologic parameters, the density of local immune cells (determined with three multiplex immunohistochemistry panels and conventional immunohistochemistry), and survival. The gene discussed is CDX2; the disease is colorectal carcinoma.